Erasca, Inc.
ERASErasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers.
Earnings
Next report
Aug 11, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with RAS/MAPK pathway-driven cancers. The company employs a modality-agnostic approach to target upstream, midstream, and downstream nodes of the signaling pathway to overcome treatment resistance and improve patient survival. Its core value proposition lies in a holistic, data-driven strategy to shut down one of the most frequently mutated oncogenic pathways in human cancer.
Erasca is a specialized clinical-stage player focusing on comprehensive RAS/MAPK pathway inhibition through a modality-agnostic pipeline.
Questions, answered.
- What is Erasca, Inc.'s market cap?
- Erasca, Inc. (ERAS) has a market capitalization of $6.6B and trades on NASDAQ.
- Who are Erasca, Inc.'s competitors?
- Erasca, Inc.'s key competitors include Revolution Medicines, Amgen, Pfizer, and others. These companies compete in similar markets and product categories.
- Who does Erasca, Inc. partner with?
- Erasca, Inc.'s notable partners include Guangzhou Joyo Pharmatech Co., Ltd., Medshine Discovery Inc., Tango Therapeutics, Inc., and others.
- What subsidiaries does Erasca, Inc. have?
- Erasca, Inc.'s subsidiaries include Erasca Ventures, ASN Product Development, Inc..
- Where is Erasca, Inc. headquartered?
- Erasca, Inc. is headquartered in United States of America and employs approximately 129 people. It has been publicly traded since 2021.